Q-Med: RESTYLANE SubQ approved in Europe

UPPSALA, Sweden, March 29, 2004 (PRIMEZONE) -- Q-Med's new product, RESTYLANE SubQ, has got a CE certification with the indication for subcutaneous tissue augmentation, recommended by Q-Med to be used for shaping the contours of the face, e.g. more pronounced cheeks and chin. The approval of RESTYLANE SubQ means that the product now can be marketed and sold in the European Union, Norway and Switzerland.

"The worldwide market for soft tissue augmentation is a fast growing market. RESTYLANE SubQ has been developed to meet the increasing demand for a less invasive treatment option with a shorter down-time," says Anna Tenstam-Lundvall, Vice President, Esthetics Business Unit.

RESTYLANE SubQ is an instant esthetic treatment creating volume for the shaping of facial contours, such as cheeks and chin. It can also be used as an alternative or complement to traditional facelifts.

"Q-Med is offering training sessions for physicians on a selective basis and thus the treatment will be available for consumers in Europe after the training is completed," concludes Tenstam-Lundvall.

RESTYLANE SubQ is based on Q-Med's patented NASHA technology just like the company's other esthetic products. The main difference between RESTYLANE SubQ and the other RESTYLANE products is the intended level of injection. RESTYLANE SubQ is intended for subcutaneous or supraperiosteal injections where large volumes are required.

Queries should be addressed to:

Anna Tenstam-Lundvall, Vice President, Esthetics Business Unit, Ph:+46(0) 70 974 90 95 Fredrik Hallstan, Manager, Investor Relations and Corporate Communications, Ph:+46(0)70-974 90 15.

Visit www.restylane.com for background material and pictures

Note: Q-Med AB operates under the name of Q-Med Scandinavia, Inc. in the USA.

Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces and markets medical implants. All products are based on the company's patented technology for the production of NASHA - Non-Animal Stabilized Hyaluronic Acid. The products RESTYLANE, RESTYLANE Touch and RESTYLANE Perlane are used for the filling out of lips and facial wrinkles. RESTYLANE is approved for sales in USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the knee joint, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Since July Q-Med today has 470 employees, with approximately 300 at the company's production facility and head office in Uppsala. The Q-Med share was first listed on the O-list of the Stockholm Stock Exchange in December 1999.

This information was brought to you by Waymaker http://www.waymaker.net

The following files are available for download:

Download release as PDF-file: http://www.waymaker.net/bitonline/2004/03/29/20040329BIT20620/wkr0006.pdf


Contact Data